Slideshow

Endo News Roundup: Promising Diabetes Therapies

Author(s):

Three new studies highlight promising diabetes drug treatments to help patients who struggle with severe hyperglycemia.

New drugs show promise in treating type 2 diabetes mellitus (T2DM) patients with severe hyperglycemia, and may also lower cardiovascular disease (CVD) risks and reduce glucose variability. Here are the highlights from three new studies: a combination of saxagliptin and metformin is effective in treating severe hyperglycemia in patients with new-onset T2DM. T2DM patients treated with dipeptidyl peptidase-4 (DPP-4) inhibitors may have lower risks for CVD as compared to those for non-DPP-4 inhibitor users, except for those taking metformin. Insulin-dependent T2DM patients show reduced glucose variability when treated with a glucagon-like peptide 1 (GLP-1) agonist.

Related Videos
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
Viet Le, DMSc, PA-C | Credit: APAC
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
Diabetes Dialogue: Latest Updates on Semaglutide Shortage, Data | Image Credit: HCPLive
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
© 2024 MJH Life Sciences

All rights reserved.